September 29, 2016 11:04 AM ET

Biotechnology

Company Overview of Banyan Biomarkers, Inc.

Company Overview

Banyan Biomarkers, Inc. develops biomarkers for the diagnosis, management, and treatment of traumatic brain injuries (TBIs). Its product pipeline includes biomarkers for stroke, depression, hypoxic ischemic encephalopathy (HIE), neuro ICU monitoring, and subacute/chronic TBI. The company also provides a point-of-care diagnostic blood test to detect the presence of mild and moderate brain trauma of head injured patients. Banyan Biomarkers, Inc. was formerly known as Daimonion Diagnostics, LLC and changed its name to Banyan Biomarkers, Inc. in July 2004. The company was founded in 2002 and is based in Alachua, Florida with an additional location in San Diego, California.

13400 Progress Boulevard

Alachua, FL 32615

United States

Founded in 2002

Phone:

386-462-6699

Fax:

386-418-2184

Key Executives for Banyan Biomarkers, Inc.

Executive Chairman and Chief Executive Officer
Age: 74
Founder, Chief Science Officer and Director
Founder and Director
Vice President of Finance
Chief Operating Officer
Compensation as of Fiscal Year 2016.

Banyan Biomarkers, Inc. Key Developments

Quanterix Corporation Announces License Agreement with Banyan Biomarkers

Quanterix Corporation announced a license agreement for research use with Banyan Biomarkers. Quanterix' Simoa platform will incorporate the Banyan UCH-L1 and Banyan GFAP assays to help further neurological research for improved TBI diagnosis and treatment.

Royal Philips and Banyan Biomarkers Partner to Develop and Commercialize New Handheld Blood Test to Detect and Evaluate Concussions

Royal Philips and Banyan Biomarkers, Inc. announced that they have entered into a multi-year joint development agreement to develop and commercialize a new handheld blood test to detect and evaluate mild traumatic brain injury (TBI) - also known as concussion - at the point of care. The new handheld test will be based on Philips’ Minicare I-20 system. The financial details of the agreement were not disclosed.

Banyan Biomarkers Reports Successful Clinical Trial Results of Blood Test to Evaluate Mild and Moderate Traumatic Brain Injury

Banyan Biomarkers, Inc. announced the results of a clinical study utilizing a blood test to evaluate mild and moderate TBI. The results, published online in the Journal of Neurotrauma, indicate that the two highly brain specific biomarkers in Banyan Biomarkers’ blood test, ubiquitin c-terminal hydrolase-L 1 (UCH-L1) and glial fibrillary acidic protein (GFAP), are detectable in blood shortly after a TBI. The test was able to identify 100% of the trial subjects who went on to have a positive computed tomography (CT) scan of the head. The results demonstrate that early biomarker testing for patients with mild to moderate TBI has the potential to provide clinicians with objective evidence needed to reduce CT use that is associated with increased healthcare costs1 and developing cancer over the long term.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Banyan Biomarkers, Inc., please visit www.banyanbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.